Other News To Note
Savient Pharmaceuticals Inc., of Bridgewater, N.J., said the European Commission granted marketing authorization to Krystexxa (pegloticase) for the treatment of severe debilitating chronic tophaceous gout in adults who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom those medications are contraindicated.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.